# A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation

> **NCT07752875** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **LG Chem** · enrollment: 250 (estimated)

## Conditions studied

- Ovarian Cancer
- Small Cell Lung Cancer
- Non Small Cell Lung Cancer
- Colorectal Cancer
- Esophageal Cancer
- Breast Cancer
- Endometrial Cancer
- Head and Neck Cancer
- Pancreatic Cancer
- Locally Advanced Unresectable or Metastatic Solid Tumor

## Interventions

- **DRUG:** LG00313112

## Key facts

- **NCT ID:** NCT07752875
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-01
- **Primary completion:** 2032-10-31
- **Final completion:** 2033-04-30
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07752875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07752875, "A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07752875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*